New hope for tough blood cancers: experimental drug MTM-H-001 enters human testing

NCT ID NCT07476378

First seen Mar 26, 2026 · Last updated May 12, 2026 · Updated 7 times

Summary

This study tests a new drug called MTM-H-001 in adults with certain blood cancers (like diffuse large B-cell lymphoma and chronic lymphocytic leukemia) that have not responded to or returned after standard treatments. The main goal is to check the drug's safety and find the right dose, while also seeing if it can shrink tumors. About 69 people will take part in this early-stage trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Langfang, Hebei, 065000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.